LET'S HEAL

Let's Test®

NEWS

Systagenix announces launch of world's first point of care test for the assessment of chronic wounds

Systagenix announced the launch of WOUNDCHEK™ Protease Status at Wounds UK in Harrogate in November. WOUNDCHEK™ Protease Status, the world's first rapid, point of care test for the assessment of protease activity in chronic wounds, will be launched outside of the United States in December 2011. Developed to aid wound assessment and help clinicians target advanced wound care therapies more effectively, WOUNDCHEK™ Protease Status is the first product arising from the collaboration between Systagenix and Alere Scarborough, a subsidiary of Alere, a global leader in rapid point of care diagnostic testing.

World premiere in Harrogate

The collaboration between Systagenix and Alere, which began in 2010, is aimed at developing a range of diagnostic tests targeting markers recommended by the 2008 World Union of Wound Healing Societies (WUWHS) consensus document which emphasized the importance of effective assessment and diagnosis in wound care.

New Consensus Documents are now available:

- International
- UK
- Italy
- Canada (English)
- Canada (French)

Systagenix

2057 December 2011

NEWS

Let's Test®

New data to show why a test that can detect EPA is clinically relevant



Dr Thomas Serena, Serena Group, Warren, PA, USA, presented a poster at Wounds UK in Harrogate in November 2011, Protease Activity Levels Associated with Healing Status of Chronic Wounds. Some of the key finding of the poster show that a chronic wound with EPA (Elevated Protease Activity) has a 90% probability that it won't heal (without appropriate intervention) but only 28% of non-healing wounds have EPA.

A test that identifies which wounds have EPA could lead to targeted treatment with a protease modulating therapy which could increase the chance of healing in these wounds.

Dr Robert Snyder, Tamarac, Florida, also presented a poster in Harrogate which looked at "The importance of proteases in wound healing and wound assessment".

Dr Snyder carried out a survey to establish clinical importance and current understanding of proteases and their impact on wound assessment and treatment choice. 97% of clinicians in the survey agreed that a Point of Care test that alerted the clinician to EPA would be useful.

One of the key conclusions from the survey was that **there are no visual cues to detect EPA** in a wound.

Can you beat the test and find EPA?

Try the EPA challenge on
http://3575651.polldaddy.com/s/woundchek-1

Let's Talk

Email us at EPA@systagenix.com to request a visit from a Systagenix representative to find out more. Alternatively, visit www.systagenix.com.

References
1. Serena T. et al. Protease activity levels associated with healing status of chronic wounds. Poster, Wounds UK 2011.
2. Snyder R, Cullen B, Nisbet L, Serena T. A SURVEY: THE IMPORTANCE Of PROTEASES IN WOUND HEALING AND WOUND ASSESSMENT. Poster, Wounds UK, 2011.
3. International consensus. The role of proteases in wound diagnostics. An expert working group review. London: Wounds International, 2011.

Systagenix